Stromedix
WebFeb 14, 2012 · WESTON & CAMBRIDGE, Mass.-- ( BUSINESS WIRE )-- Biogen Idec (NASDAQ: BIIB) and Stromedix, Inc. today announced that they have entered into a definitive … WebAug 31, 2010 · CAMBRIDGE, Mass., August 31, 2010 – Stromedix, Inc., a biotechnology company focused on innovative therapies for fibrosis and fibrotic organ failure, …
Stromedix
Did you know?
WebStromedix, Inc. develops drugs to treat fibrotic organ failure. The Company offers a humanized monoclonal antibody that provides anti-fibrotic activity in preclinical models of … WebPrior to founding Stromedix in 2006, from 1999 to 2005, Dr. Gilman served in a variety of capacities, most recently as Executive Vice President, Research at Biogen Idec. From 1994 to 1999, Dr. Gilman was at ARIAD Pharmaceuticals, Inc., where he was Executive Vice President and Chief Scientific Officer. From 1986 to 1994, Dr. Gilman was on the ...
WebApr 9, 2009 · This Phase 2 study is a multi-center, randomized, double-blind, placebo-controlled, single followed by multiple dose, dose escalation study designed to evaluate the safety, tolerability, pharmacokinetics, immunogenicity, and impact of STX-100 on gene and protein expression for αvβ6 related and TGF-β-inducible genes (including tubulointerstitial … WebOct 15, 2004 · Biogen Buys VC-Backed Stromedix. Feb 14, 2012. View all articles. Red Abbey Venture Partners Investments. 37 Investments. Red Abbey Venture Partners has made 37 investments. Their latest investment was in Perceiv AI as part of their Seed VC on December 12, 2024. Red Abbey Venture Partners Investments Activity. View Investments Chart. …
WebFind company research, competitor information, contact details & financial data for Stromedix, Inc. of Cambridge, MA. Get the latest business insights from Dun & Bradstreet. … WebCompany Type For Profit. Contact Email [email protected]. Phone Number 617.674.8400. Stromedix will focus initially on chronic indications but plans to leverage …
WebHe previously served on the boards of past Atlas companies Avila (acquired by Celgene), Padlock (acquired by BMS), Prestwick (acquired by Biovail), Stromedix (acquired by Biogen), Zafgen (NASDAQ:ZFGN), and a number of other ventures. Bruce serves as an advisor in various capacities to UCB, Takeda, and the Gates Foundation.
WebSep 17, 2024 · Biogen paid $75 million upfront to acquire Stromedix in 2012, lining up nearly $500 million in potential milestone payments. Phase 2b testing of BG00011 began in … pinsa italienischWebThe drug was originally developed by Stromedix, a biotech founded and ran by a former Biogen executive, Michael Gilman. Biogen paid $75 million upfront to acquire Stromedix in 2012, lining up nearly $500 million in potential milestone payments. haimasyöpä hoitoWebNov 21, 2016 · 4. Consider your role, present and future. If a biotech startup succeeds, it’s likely to change. It will bring on more people, often growing very quickly. It will expand into clinical studies, and if it doesn’t get acquired by a larger company—a very common occurrence in a biotech that shows promise in the clinic—it will take on a ... pinsa kcal vapianoWebFeb 14, 2012 · From an investment viewpoint, Stromedix is a very good deal for us. It raised only $38M in equity capital over its five-year life. The $75M upfront secures a positive return prior to the Phase 2 ... pinsaku 検索WebPrior to founding Stromedix in 2006, Mike served as Executive Vice President, Research at Biogen Idec, with responsibility for the company’s discovery research activities in Cambridge and San Diego. From 1994 to 1999, Mike was at ARIAD Pharmaceuticals, where he was Executive Vice President and Chief Scientific Officer. haima suvWebSummary. Founder of Infinity Pharmaceuticals, Inc., DNX Corp., Biotechnology Innovation Organization and Shoreline Biosciences, Inc., Steven H. Holtzman is an American entrepreneur and businessperson who has been at the head of 6 different companies and currently is Chairman of Camp4 Therapeutics Corp., Chairman for Hangzhou Qihan … pinsa idsteinWebPrior to joining Atlas in 2005, Bruce was a consultant at McKinsey & Company, as well as an investor for Caxton Health Holdings. As a British Marshall Scholar, Bruce received a D.Phil. (PhD) in molecular immunology from Oxford University. He received a BS in biochemistry, summa cum laude, from The Pennsylvania State University. hai master kitchen